Published in Obesity and Diabetes Week, May 8th, 2006
According to a recent review from New Zealand, "Diabetic nephropathy is the leading cause of chronic renal failure in countries in the western world. Human polymorphism studies have suggested a nephroprotective effect that is mediated by bradykinin B2 receptors."
"Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers have an additive nephroprotective effect in patients with diabetes, which may be due to ACE-inhibitor-mediated increases in the levels of bradykinin. There is also evidence from studies conducted in genetically altered mice to suggest...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.